This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nimer, S. D. Search for Related Content PubMed PubMed Citation Articles by Nimer, S. D. Social Bookmarking                            What's this?

Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q

Stephen D. Nimer

From the Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Stephen D. Nimer, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 575, New York, NY 10021-6007; e-mail: s-nimer{at}mskcc.org

Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q– syndrome. Del(5q) MDS patients frequently have symptomatic anemia, and its treatment has traditionally consisted of RBC transfusions and, for some, iron chelation therapy. Erythropoietin, darbepoetin, hypomethylating agents, and lenalidomide can enhance erythropoiesis in MDS patients with anemia, increasing hemoglobin levels and abrogating RBC transfusion requirements. Lenalidomide is particularly active in treating the anemia of del(5q) MDS, which is especially relevant given the low response rate to erythropoietin in this group of patients. In a recent study of 43 MDS patients, 10 of 12 patients (83%) with del(5q) MDS achieved sustained RBC transfusion independence (or a > 2 g/dL increase in hemoglobin), compared with 57% of those with a normal karyotype and 12% of those with other karyotypic abnormalities. Complete cytogenetic remissions were achieved in 75% (nine of 12) of the del(5q) MDS patients, suggesting that lenalidomide targets a fundamental pathogenetic feature of MDS that is more pronounced in the presence of chromosomal 5q deletions. This review highlights some issues about the classification and treatment of del(5q) MDS.

Supported by a Leukemia Lymphoma Society SCOR grant, the Rosemary Breslin Research Fund, and the Renny Saltzman Research Fund.

This article was written in memory of the late David Golde, MD.

Author's disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF]

				M. Mallo, L. Arenillas, B. Espinet, M. Salido, J. M{a} Hernandez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro, P. Font, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- Haematologica, July 1, 2008; 93(7): 1001 - 1008. [Abstract] [Full Text] [PDF]